Alphyn Biologics is the leader developing a new class of drugs called Multi-target Therapeutics based on the therapeutic capabilities of its patent-pending AB-101 platform biomaterial.  Alphyn’s AB-101 has over 40 bio-active compounds which provide Alphyn a rich and deep therapeutic product pipeline to treat and cure multiple diseases having no therapy or therapies with less than optimal results.

Alphyn includes all of AB-101’s bio-active compounds in each of its therapeutic products.  The result is all Alphyn therapeutics have multiple compounds attacking the target disease providing multiple ways to treat and cure each disease.  As multi-target therapeutics, Alphyn’s products are anticipated to be highly effective because AB-101 is expected to force the target disease to overcome multiple methods of attack.  Alphyn’s therapeutics forcing the target disease to overcome multiple methods of attack should reduce the possibility of, or extend the time for, the disease to develop resistance to Alphyn’s products.

By including all of AB-101’s bio-active compounds in each Alphyn therapeutic product, Alphyn’s therapeutics can follow an accelerated timeline and reduced-cost path to FDA drug approval compared to standard drugs.

Alphyn is leading the way to more powerful and effective therapies.  The use of all of AB-101’s bio-active compounds in Alphyn’s products establishes a new class of drugs – Multi-target Therapeutics.

The first product in Alphyn’s pipeline is its MRSA-1 Topical Antibiotic.  MRSA-1 in laboratory testing has demonstrated it is effective against a variety of different bacteria (i.e., a ‘broad-spectrum’ antibiotic) and effective against drug-resistant bacteria, including MRSA, mupirocin resistant MRSA and multidrug-resistant (MDR) Pseudomonas aeruginosa.

Alphyn has conducted a successful FDA Pre-IND meeting for MRSA-1 resulting in Alphyn’s expectation MRSA-1 will continue its accelerated timeline and reduced-cost path to FDA drug approval.

While Alphyn has many potential disease targets, the Company projects its second product in its pipeline will be it Cancer-1, a topical therapy to treat basal cell carcinoma.  Cancer-1 is expected to be effective without the side effects of the current treatments, and, is expected to follow the same accelerated timeline and reduced-cost path to FDA drug approval.